Measuring Treatment Tolerability In Oncology: Expert Panel Discussion

Traditional adverse event reporting often fails to capture the full spectrum of treatment burden, with research suggesting that nearly half of patient-reported symptoms are missed in oncology trials. For pharmaceutical sponsors, the challenge lies in developing robust strategies that translate these subjective experiences into structured, actionable data that satisfies both regulatory bodies and internal development milestones.

This presentation features oncology leaders from industry and academia exploring the transition from isolated safety tracking to a comprehensive understanding of patient tolerability. The discussion focuses on implementing phase-appropriate PRO measures and the strategic integration of patient-centered data into clinical submissions and product labeling. By bridging the gap between individual events and the holistic patient experience, sponsors can generate deeper insights that significantly strengthen the value proposition of their oncology programs.